ERBB2 and gastric cancer: According to our study, in advanced gastric cancer, HER2 positive cases by plasma cfDNA ddPCR may be candidates for trastuzumab treatment, but HER2 assessment by other methods using tissue samples should be done in HER2 negative cases by ddPCR of plasma cfDNA to overcome low sensitivity.